Featuring proprietary OXINIUM™ DH material; eliminates cobalt chrome Alloy to reduce wear and corrosion risks1
September 20, 2022 –
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced the launch of its OR3O Dual Mobility System for use in primary and revision total hip arthroplasty in Japan. Compared to traditional solutions, dual mobility implants have a smaller diameter femoral head that snaps into a larger polyethylene liner – increasing stability, reducing the risk of dislocation and providing an improved range of motion.2
While most competing devices use a Cobalt Chrome (CoCr) liner along with CoCr or ceramic head balls, OR3O incorporates Smith+Nephew’s latest advanced bearing surface, OXINIUM DH, for its liner and proprietary OXINIUM on XLPE for its femoral head and polyethylene inserts . This eliminates both the modular CoCr liner and/or CoCr head ball from the construct – reducing wear and corrosion risks that have been associated with the alloy.1
OXINIUM DH (Diffusion Hardened) is a unique variant of Smith+Nephew’s OXINIUM technology platform that increases the depth of cure through an additive manufacturing process.
The modular dual mobility segment was launched in Japan in 2013 and has continued to grow globally. Postoperative dislocation is the second most common reason for revision of a total hip replacement worldwide3-6 and remains a serious problem for surgeons performing total hip arthroplasty. Studies have shown that the dual mobility is uniquely positioned to better manage dislocations than large metal-to-metal or ceramic-to-ceramic head series.7
“Smith+Nephew’s OR3O dual mobility system is a groundbreaking launch for Japan that offers technology unavailable in competing systems,” said Shinya Dobashi, senior vice president and managing director, North Asia, Smith+Nephew. “Over a dozen peer-reviewed publications have now cited or raised concerns about corrosion or elevated ions in CoCr modular dual mobility liners.8-20 The reduced corrosion1 our OXINIUM and OXINIUM DH treads sets OR3O apart from the competition.”
Smith+Nephew’s OR3O™ dual mobility system is available in Japan for both primary and revision applications and offers cross-compatibility with the R3™ acetabular system.
|David Snyder||+1 978-749-1440|
|blacksmith + nephew|
- Parich A; Pawar V.; Sprague J. Long term simulator wear performance of an advanced bearing technology for THA. Poster presented at ORS. 2013; Poster No.: 1028
- Darrith B, Courtney PM, Della Valle CJ Outcomes of dual mobility components in total hip arthroplasty. Bone joint J 2018;100-B:11-19.
- Australian Orthopedic Association National Joint Replacement Registry (AOANJRR). hips, knees &
- Shoulder Arthroplasty: 2021: Annual Report 2021, Adelaide; AOA, 2021: [Available at: https://aoanjrr.sahmri.com/annual-reports-2021]
- National Common Register for England, Wales and Northern Ireland, 18th Annual Report [Available at: https://reports.njrcentre.org.uk/downloads]
- American Joint Replacement Registry (AJRR), The Seventh Annual Report of the AJRR on Hip and Knee Arthroplasty 2021, American Academy of Orthopedic Surgeons
- Italian Arthroplasty Register, Supplement to Annual Report 2019, English Version of Tables and Figures, October 2020
- Boyer, B., Philippot, R., Lower, J. & Farizon, F. (2011). “Primary total hip arthroplasty with dual mobility cup to avoid dislocations: a 22-year follow-up of 240 hips,” International Orthopedics (SICOT) (2012) 36:511–518
- Spece H, MacDonald DW, Mont MA, Lee GC, and Kurtz SM, Fretting Corrosion and Polyethylene Damage Mechanisms in Modular Dual Mobility Total Hip Arthroplasty, Beyond the Implant: Retrieval Analysis Methods for Implant Monitoring, ASTM STP1606
- Nam D, Salih R, Nahhas C, Barrack R and Nunley R (2019). “Is a dual mobility modular acetabulum a viable option for the young, active total hip arthroplasty patient?”, Bone Joint J 2019;101-B:365-371
- Matsen Ko L, Pollag K, Yoo J, & Sharkey P (2015). “Serum Metal Ion Levels After Total Hip Arthroplasty Using ModularDual Mobility Components”, The Journal of Arthroplasty 31 (2016) 186–189
- Civinini R, Cozzi Lepri A, Carulli C, Matassi F, Villano M, & Innocenti M (2019). “Patients following revision total hip arthroplasty with ModularDual mobility components and cobalt-chromium internal metal head are exposed to elevated serum metal ion levels”, The Journal of Arthroplasty 35 (2020) S294eS298
- Romero, J., Wach, A., Silberberg, S., Chiu, Y., Westrich, G., Wright, T., & Padgett, D. (2020) Otto-Aufranc-Prize 2020: Malseating of modular dual mobility liners Occurrence and Impact’, Bone Joint J 2020;102-B(7 Supple B):20–26
- Lee G, Kamath A & Maxwell Courtney P (2020). “Clinical Concerns with Dual Mobility – Should I Avoid Them If Possible?” Article in press, The Journal of Arthroplasty xxx (2021) 1e4
- Gkiatas I, Sharma A, Greenberg A, Duncan S, Chalmers B & Sculco P (2020). “Serum Metal Ion Levels in Modular Dual Mobility Acetabular Components: A Systematic Review,” Journal of Orthopedics 21 (2020) 432–437
- Steven M. Kurtz et al. (2015) “Is there material loss at the posterior taper of CoCr modular acetabular inserts?”, Clinical Orthopedics and Related Research, 473:275–285
- Lombardo D, Siljander M, Gehrke C, Moore D, Karadsheh M & Bäcker E (2018). “Fretting and Corrosion Damage of Retrieved Dual-Mobility Total Hip Arthroplasty Systems,” The Journal of Arthroplasty 34 (2019) 1273e1278
- Kolz J, Wyles C, Van Citters D, Chapman R, Trousdale R & Beere D (2020). “In vivo corrosion of modular dual mobility implants: A retrieval study”, The Journal of Arthroplasty 35 (2020) 3326e3329
- Sohn, K. & Meneghini, R. (2020). ‘Case report: Adverse Local Tissue Reaction due to Acetabulum Corrosion in Modular Dual-Mobility Constructs’, Arthroplasty Today 6 (2020) 976e980
- Tarity T, Koch C, Burket J, Wright T & Westrich G (2016). “Fretting and Corrosion at the Backside of Modular Cobalt Chromium Acetabular Inserts: A Retrieval Analysis”, The Journal of Arthroplasty 32 (2017) 1033e1039
- Markel DC, Bou-Akl T, Rossi MD, Pizzimenti N, Wu B, Ren W (2019). “Blood metal levels, leukocyte profiles, and cytokine profiles in patients with a dual mobility modular hip prosthesis: Early results of a prospective cohort study,” Bone Joint J 2019;101-B:1035–1041
Smith+Nephew is a medical technology portfolio company focused on soft and hard tissue repair, regeneration and replacement. We exist to restore people’s bodies and their confidence, using technology to set limits to life. We call this purpose Life Unlimited. Our 18,000 employees fulfill this mission every day by improving patients’ lives through the excellence of our product portfolio and the invention and application of new technologies across our three global franchises Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in 1856 in Hull, UK, the company now operates in more than 100 countries and had annual sales of US$5.2 billion in 2021. Smith+Nephew is a component of the FTSE100 (LSE:SN, NYSE:SNN). The terms “Group” and “Smith+Nephew” refer to Smith & Nephew plc and its consolidated subsidiaries unless the context otherwise requires.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us TwitterLinkedIn, Instagram or Facebook.
This document may contain forward-looking statements, which may or may not prove to be correct. For example, statements regarding expected sales growth and trading margins, market trends and our product pipeline are forward-looking statements. Expressions such as “aim”, “plan”, “intend”, “anticipate”, “well positioned”, “believe”, “estimate”, “expect”, “aim”, “consider” and similar expressions are generally intended to be construed identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied by the statements. For Smith+Nephew, these factors include: Risks related to the impact of COVID-19, such as: B. the depth and duration of its impact, governmental and other restrictive measures taken in response, material delays and cancellations of electoral processes, reduced processing capacity at medical facilities, limited access for sales associates to medical facilities, or our ability to ensure business continuity – execute plans as a result of COVID-19; economic and financial conditions in the markets we serve, particularly those affecting healthcare providers, payers and customers (including but not limited to as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; governmental approvals, reimbursement decisions or other governmental actions; product defects or recalls or other quality management system issues or non-compliance with applicable regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including but not limited to as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and divestitures; our success in conducting due diligence, valuation and integration of acquired businesses; disruptions that may result from transactions or other changes we make to our business plans or organization to adapt to market developments; and numerous other matters affecting us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to Smith+Nephew’s filings with the US Securities and Exchange Commission under the US Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent Annual Report on Form 20-F, to discuss some of these factors. Any forward-looking statement is based on information available to Smith+Nephew at the time the statement is made. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this cautionary statement. Smith+Nephew undertakes no obligation to update or revise any forward-looking statements to reflect changes in circumstances or Smith+Nephew’s expectations.
◊ trademarks of Smith+Nephew. Certain marks are registered in the US Patent and Trademark Office.